Companies waver in efforts to target transforming growth factor beta in cancer

J Natl Cancer Inst. 2009 Dec 16;101(24):1664-7. doi: 10.1093/jnci/djp462.
No abstract available

Publication types

  • News

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / pharmacology*
  • Cell Proliferation / drug effects
  • Clinical Trials as Topic / trends
  • Combined Modality Therapy
  • Drug Industry / trends*
  • Humans
  • Immunotherapy / methods
  • Mice
  • Mice, Transgenic
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Oligonucleotides, Antisense / immunology
  • Precision Medicine
  • Protein Kinase Inhibitors / pharmacology
  • Transforming Growth Factor beta / adverse effects*
  • Transforming Growth Factor beta / antagonists & inhibitors*
  • Transforming Growth Factor beta / genetics
  • Transforming Growth Factor beta / immunology
  • Transforming Growth Factor beta / metabolism

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Oligonucleotides, Antisense
  • Protein Kinase Inhibitors
  • Transforming Growth Factor beta